Active Colitis

Crohn disease (CD) and ulcerative colitis (UC) are forms of inflammatory bowel disease. The severity of the disease varies widely among patients. Researchers have now identified a gene expression profile that can predict prognosis in patients with CD and

The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

Janssen Biotech, Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved REMICADE (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate respon

MONDAY, Sept. 26 (HealthDay News) -- Remicade (infliximab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe active episodes of ulcerative colitis in children aged six and older who haven't responded to other therapies

From the 50,000 to 100,000 children in the United States suffering from inflammatory bowel disease (IBD), 40% are affected by ulcerative colitis (UC). UC, a form of inflammatory bowel disease (IBD) affects the lining of the large intestine (colon) and rec